ReviewProbiotics and antimicrobial proteins2026
Natural and synthetic antimicrobial peptides against anaerobic bacteria: A review of activities and mechanisms of action.
Review in Probiotics and antimicrobial proteins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anaerobic bacteria cause a wide range of infections, varying from mild to severe, whether localized, implant-associated, or invasive, often leading to high morbidity and mortality. These infections are challenging to manage due to antimicrobial resistance against common antibiotics such as carbapenems and nitroimidazoles. The empirical use of antibiotics has contributed to the emergence of resistant organisms, making the identification and development of new antibiotics increasingly difficult. This highlights the need for adjuvant treatments. Antimicrobial peptides (AMPs) have garnered attention as promising agents in combating resistant bacteria. Researchers are interested in AMPs due to their broad-spectrum activity, multiple mechanisms of action, and reduced likelihood of inducing resistance. Moreover, AMPs can enhance the effectiveness of conventional antibiotics through synergistic effects. Researchers suggest that AMPs could play a valuable role in the development of new drugs targeting anaerobic pathogens. Exploring the properties and functions of these peptides represents a significant step toward alternative therapies. This paper reviews natural and synthetic AMPs derived from various sources that target different cellular components and functions of anaerobic bacteria, including Actinomyces, Fusobacterium, Bacteroides, Porphyromonas, Prevotella, Clostridium, Clostridioides, Lactobacillus, Peptostreptococcus, Propionibacterium, Bifidobacterium, Veillonella, and Tannerella. The described AMPs act on the cell membrane, peptidoglycan, lipopolysaccharide (LPS), biofilms, ion channels, toxins, DNA, transcription, and translation. The data indicate that these peptides demonstrate significant potential against anaerobes, presenting a promising strategy for combating antibiotic resistance.
Indexed as
Identifiers
40924369What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.